Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

82,288 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Final overall survival data of sintilimab plus pemetrexed and platinum as First-Line treatment for locally advanced or metastatic nonsquamous NSCLC in the Phase 3 ORIENT-11 study.
Zhang L, Wang Z, Fang J, Yu Q, Han B, Cang S, Chen G, Mei X, Yang Z, Stefaniak V, Lin Y, Wang S, Zhang W, Sun L, Yang Y. Zhang L, et al. Among authors: zhang w. Lung Cancer. 2022 Sep;171:56-60. doi: 10.1016/j.lungcan.2022.07.013. Epub 2022 Jul 19. Lung Cancer. 2022. PMID: 35917647 Clinical Trial.
Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11).
Yang Y, Wang Z, Fang J, Yu Q, Han B, Cang S, Chen G, Mei X, Yang Z, Ma R, Bi M, Ren X, Zhou J, Li B, Song Y, Feng J, Li J, He Z, Zhou R, Li W, Lu Y, Wang Y, Wang L, Yang N, Zhang Y, Yu Z, Zhao Y, Xie C, Cheng Y, Zhou H, Wang S, Zhu D, Zhang W, Zhang L. Yang Y, et al. Among authors: zhang l, zhang w, zhang y. J Thorac Oncol. 2020 Oct;15(10):1636-1646. doi: 10.1016/j.jtho.2020.07.014. Epub 2020 Aug 8. J Thorac Oncol. 2020. PMID: 32781263 Free article. Clinical Trial.
Sintilimab Plus Platinum and Gemcitabine as First-Line Treatment for Advanced or Metastatic Squamous NSCLC: Results From a Randomized, Double-Blind, Phase 3 Trial (ORIENT-12).
Zhou C, Wu L, Fan Y, Wang Z, Liu L, Chen G, Zhang L, Huang D, Cang S, Yang Z, Zhou J, Zhou C, Li B, Li J, Fan M, Cui J, Li Y, Zhao H, Fang J, Xue J, Hu C, Sun P, Du Y, Zhou H, Wang S, Zhang W. Zhou C, et al. Among authors: zhang l, zhang w. J Thorac Oncol. 2021 Sep;16(9):1501-1511. doi: 10.1016/j.jtho.2021.04.011. Epub 2021 May 25. J Thorac Oncol. 2021. PMID: 34048947 Free article. Clinical Trial.
Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial.
Lu S, Wu L, Jian H, Chen Y, Wang Q, Fang J, Wang Z, Hu Y, Sun M, Han L, Miao L, Ding C, Cui J, Li B, Pan Y, Li X, Ye F, Liu A, Wang K, Cang S, Zhou H, Sun X, Ferry D, Lin Y, Wang S, Zhang W, Zhang C. Lu S, et al. Among authors: zhang c, zhang w. Lancet Oncol. 2022 Sep;23(9):1167-1179. doi: 10.1016/S1470-2045(22)00382-5. Epub 2022 Jul 28. Lancet Oncol. 2022. PMID: 35908558 Clinical Trial.
[Management of Rheumatic Adverse Events Related to Immune Checkpoint Inhibitors].
Zhou J, Wang Q, Duan L, Si X, Zhang L, Liu X, Li Y, Wang H, Guo X, Zhang W, Zhang L. Zhou J, et al. Among authors: zhang l, zhang w. Zhongguo Fei Ai Za Zhi. 2019 Oct 20;22(10):671-675. doi: 10.3779/j.issn.1009-3419.2019.10.12. Zhongguo Fei Ai Za Zhi. 2019. PMID: 31650952 Free PMC article. Review. Chinese.
Management of immune checkpoint inhibitor-related rheumatic adverse events.
Zhou J, Wang H, Guo X, Wang Q, Duan L, Si X, Zhang L, Liu X, Li Y, Zhang W, Zhang L. Zhou J, et al. Among authors: zhang l, zhang w. Thorac Cancer. 2020 Jan;11(1):198-202. doi: 10.1111/1759-7714.13249. Epub 2019 Nov 24. Thorac Cancer. 2020. PMID: 31762209 Free PMC article.
Thrombocytopenia Is an Independent Risk Factor for the Prognosis of Thrombotic Microangiopathy in Chinese Patients With Systemic Lupus Erythematosus.
Yang F, Tian J, Peng L, Zhang L, Liu J, Tian X, Zhang W, Li M, Zhao Y, Zhang F, Zeng X, Wang L, Leng X. Yang F, et al. Among authors: zhang l, zhang f, zhang w. Front Med (Lausanne). 2021 Nov 8;8:772607. doi: 10.3389/fmed.2021.772607. eCollection 2021. Front Med (Lausanne). 2021. PMID: 34820404 Free PMC article.
The role of anti-ribosomal P autoantibodies in the prediction of neuropsychiatric damage in systemic lupus erythematosus based on CSTAR cohort (XIV).
Ding Y, Zhao J, Qian J, Zhang L, Zhang S, Jiang N, Li J, Wu C, Wu Q, Xu D, Leng X, Wang Q, Zhang W, Tian X, Li M, Zeng X. Ding Y, et al. Among authors: zhang l, zhang s, zhang w. Clin Rheumatol. 2022 May;41(5):1371-1379. doi: 10.1007/s10067-021-06034-6. Epub 2022 Jan 27. Clin Rheumatol. 2022. PMID: 35083563
82,288 results
You have reached the last available page of results. Please see the User Guide for more information.